| Examining the safety of PPAR agonists - current trends and future prospects. | |
| | |
MedLine Citation:
|
PMID: 23134541 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Introduction: The peroxisome proliferator-activated receptor (PPAR)-α and -γ agonists, fibrates and glitazones, are effective treatments for dyslipidemia and type 2 diabetes mellitus, respectively, but exhibit class-related, as well as compound-specific safety characteristics. Areas covered: This article reviews the profiles of PPAR-α, PPAR-γ, and dual PPAR-α/γ agonists with regard to class-related and compound-specific efficacy and adverse effects. We explore how learnings from first-generation drugs are being applied to develop safer PPAR-targeted therapies. Expert opinion: The finding that rosiglitazone may increase risk for cardiovascular events has led to regulatory guidelines requiring demonstration of cardiovascular safety in appropriate outcome trials for new type 2 diabetes mellitus drugs. The emerging data on the possibly increased risk of bladder cancer with pioglitazone may prompt the need for post-approval safety studies for new drugs. Since PPAR-α and -γ affect key cardiometabolic risk factors (diabetic dyslipidemia, insulin resistance, hyperglycemia, and inflammation) in a complementary fashion, combining their benefits has emerged as a particularly attractive option. New PPAR-targeted therapies that balance the relative potency and/or activity toward PPAR-α and -γ have shown promise in retaining efficacy while reducing potential side effects. |
| | |
Authors:
|
Michele Bortolini; Matthew B Wright; Martin Bopst; Bogdana Balas |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-8 |
Journal Detail:
|
Title: Expert opinion on drug safety Volume: - ISSN: 1744-764X ISO Abbreviation: Expert Opin Drug Saf Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-8 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101163027 Medline TA: Expert Opin Drug Saf Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
F. Hoffmann-La Roche, Ltd, PDS-Safety Risk Management , 663/2028, CH4070 Basel , Switzerland +41 61 687952 ; michele.bortolini@roche.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Elective segmental ureterectomy for transitional cell carcinoma of the ureter: long-term follow-up i...
Next Document: Theoretical Study on CuCl-Catalyzed Coupling of Thiol Esters with Organostannane.